

Michael Heuser

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/152450/michael-heuser-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

296
papers

11,305
citations

55
h-index

101
g-index

319
ext. papers

14,323
ext. citations

5
avg, IF

5.75
L-index

#	Paper	IF	Citations
296	Reduced intensity hematopoietic stem cell transplantation for myelofibrosis in accelerated-phase.. <i>Blood Advances</i> , 2022 ,	7.8	2
295	A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2. <i>Journal of Medicinal Chemistry</i> , 2021 ,	8.3	2
294	Allogeneic, CD34 +, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease. <i>Blood</i> , 2021 , 138, 1745-1745	2.2	0
293	EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia. <i>Blood</i> , 2021 , 138, 610-610	2.2	1
292	Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications. <i>Blood</i> , 2021 , 138, 692-692	2.2	0
291	Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021 , 138, 611-611	2.2	
290	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021 , 11, 164	7	6
289	2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. <i>Blood</i> , 2021 ,	2.2	33
288	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. <i>Annals of Hematology</i> , 2021 , 100, 1181-1194	3	8
287	A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. <i>Blood Advances</i> , 2021 , 5, 1760-1769	7.8	6
286	Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite. <i>Cancers</i> , 2021 , 13,	6.6	3
285	Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. <i>American Journal of Hematology</i> , 2021 , 96, E207-E210	7.1	0
284	Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. <i>Blood Advances</i> , 2021 , 5, 2294-2304	7.8	8
283	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with -mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. <i>Haematologica</i> , 2021 , 106, 2986-2989	6.6	1
282	Induced dendritic cells co-expressing GM-CSF/IFN- γ /WT1 priming T and B cells and automated manufacturing to boost GvL. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021 , 21, 621-641	6.4	2
281	Treatment for Relapsed/Refractory Acute Myeloid Leukemia. <i>HemaSphere</i> , 2021 , 5, e572	0.3	4
280	Evidence for a low-penetrant extended phenotype of rhabdoid tumor predisposition syndrome type 1 from a kindred with gain of SMARCB1 exon 6. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e29185	3	

279	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. <i>Blood</i> , 2021 , 137, 3093-3104	2.2	19
278	Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123. <i>Viruses</i> , 2021 , 13,	6.2	2
277	Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. <i>Haematologica</i> , 2021 , 106, 565-573	6.6	13
276	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. <i>Leukemia</i> , 2021 , 35, 62-74	10.7	34
275	Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up. <i>Annals of Hematology</i> , 2021 , 100, 595-599	3	2
274	IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis. <i>Leukemia</i> , 2021 , 35, 1301-1316	10.7	7
273	Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 349-359	2.9	1
272	Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 95.e1-95.e4		4
271	Newly diagnosed isolated myeloid sarcoma-paired NGS panel analysis of extramedullary tumor and bone marrow. <i>Annals of Hematology</i> , 2021 , 100, 499-503	3	1
270	Germline variants drive myelodysplastic syndrome in young adults. <i>Leukemia</i> , 2021 , 35, 2439-2444	10.7	11
269	Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype. <i>Genes Chromosomes and Cancer</i> , 2021 , 60, 452-457	5	0
268	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2021 ,	10.7	4
267	A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3192-3203	1.9	1
266	Rationalization of the activity Profile of Pyruvate Kinase Isozyme M2 (PKM2) Inhibitors using 3D QSAR. <i>Current Topics in Medicinal Chemistry</i> , 2021 , 21, 2258-2271	3	1
265	Measurable Residual Disease in AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, S116-S118	2	
264	Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI. <i>Blood Advances</i> , 2021 , 5, 4485-4499	7.8	0
263	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. <i>Blood</i> , 2020 , 136, 157-170	2.2	72
262	A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020 , 190, e169-e173	4.5	4

261	Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. <i>Leukemia</i> , 2020 , 34, 2951-2963	10.7	7
260	The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408). <i>Blood</i> , 2020 , 136, 14-14	2.2	0
259	IDH Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML. <i>Blood</i> , 2020 , 136, 32-33	2.2	
258	Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial. <i>Blood</i> , 2020 , 136, 9-10	2.2	
257	Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML). <i>Blood</i> , 2020 , 136, 42-42	2.2	
256	Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia. <i>Blood</i> , 2020 , 136, 17-18	2.2	1
255	First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease. <i>Blood</i> , 2020 , 136, 8-9	2.2	2
254	Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls. <i>Blood</i> , 2020 , 136, 18-19	2.2	3
253	CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. <i>Blood</i> , 2020 , 136, 387-400	2.2	17
252	Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia. <i>Cancers</i> , 2020 , 12,	6.6	8
251	FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia. <i>British Journal of Haematology</i> , 2020 , 188, e11-e15	4.5	14
250	Gemtuzumab Ozogamicin in -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 623-632	2.2	35
249	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2x2, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 257-270	2.2	30
248	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020 , 4, 4945-4954	7.8	13
247	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 92	22.4	17
246	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. <i>Leukemia</i> , 2020 , 34, 2903-2913	2.7	18
245	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020 , 26, 1549-1556	50.5	118
244	Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3287-3305	1.9	2

243	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. <i>Blood</i> , 2020 , 136, 3041-3050	2.2	30
242	Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. <i>Blood Advances</i> , 2020 , 4, 6342-6352	7.8	11
241	In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. <i>Leukemia</i> , 2020 , 34, 416-426	10.7	9
240	Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia. <i>Haematologica</i> , 2020 , 105, 1294-1305	6.6	4
239	Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia. <i>Annals of Hematology</i> , 2020 , 99, 1415-1417	3	0
238	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020 , 135, 371-380	2.2	53
237	Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation. <i>European Journal of Haematology</i> , 2019 , 103, 552-557	3.8	8
236	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. <i>Blood</i> , 2019 , 134, 1608-1618	2.2	45
235	Message from the void: MRD analysis from ctDNA. <i>Blood</i> , 2019 , 133, 2631-2633	2.2	1
234	Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. <i>Annals of Hematology</i> , 2019 , 98, 1905-1918	3	31
233	How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 411-420	7.1	9
232	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. <i>Nature Communications</i> , 2019 , 10, 2031	17.4	63
231	Emerging strategies to target the dysfunctional cohesin complex in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2019 , 23, 525-537	6.4	7
230	Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2019 , 37, 375-385	2.2	97
229	Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies. <i>Human Gene Therapy</i> , 2019 , 30, 381-401	4.8	27
228	Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. <i>Blood</i> , 2019 , 133, 2233-2242	2.2	60
227	ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF. <i>Leukemia</i> , 2019 , 33, 99-109	10.7	10
226	Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN- γ and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1891-1899	7.4	7

225	Diagnostik und Management des myelodysplastischen Syndroms. <i>Onkologe</i> , 2019 , 25, 994-1003	0.1	0
224	Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7010-7010	2.2	3
223	First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7043-7043	2.2	3
222	Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG). <i>Blood</i> , 2019 , 134, 2740-2740	2.2	
221	Efficacy of Chemotherapy, Phd-Inhibitor Molidustat or BRD4 Inhibitor JQ1 in Combination with Targeted Inhibition of Mutated IDH1 in Human AML In Vivo. <i>Blood</i> , 2019 , 134, 3933-3933	2.2	
220	The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia. <i>Cancers</i> , 2019 , 11,	6.6	4
219	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Leukemia</i> , 2019 , 33, 379-389	10.7	287
218	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with -ITD. <i>Blood</i> , 2019 , 133, 840-851	2.2	141
217	Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. <i>Leukemia</i> , 2019 , 33, 1313-1323	10.7	6
216	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. <i>Blood</i> , 2019 , 133, 1140-1151	2.2	61
215	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. <i>Leukemia</i> , 2019 , 33, 1124-1134	10.7	17
214	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. <i>Leukemia</i> , 2019 , 33, 1747-1758	10.7	88
213	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2018 , 131, 1275-1291	2.2	528
212	Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome. <i>Haematologica</i> , 2018 , 103, 614-625	6.6	13
211	DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. <i>Leukemia</i> , 2018 , 32, 30-37	10.7	41
210	RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo. <i>Leukemia</i> , 2018 , 32, 224-226	10.7	10
209	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial. <i>Leukemia</i> , 2018 , 32, 1621-1630	10.7	53
208	Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study. <i>Blood</i> , 2018 , 132, 81-81	2.2	5

207	Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group. <i>Blood</i> , 2018 , 132, 1501-1501	2.2	3
206	Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmacodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study.. <i>Journal of Clinical</i>	2.2	1
205	The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 70-70	2.2	1
204	T Regulatory Cell Receptor Repertoire Focusing and Clonal Expansion Indicates Control of Acute GvHD after Donor Lymphocyte Infusion. <i>Blood</i> , 2018 , 132, 822-822	2.2	
203	Chromothripsis is linked to alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype. <i>Haematologica</i> , 2018 , 103, e17-e20	6.6	31
202	Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia. <i>Haematologica</i> , 2018 , 103, 246-255	6.6	5
201	Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2018 , 22, 107-121	6.4	16
200	Epigenetics in myelodysplastic syndromes. <i>Seminars in Cancer Biology</i> , 2018 , 51, 170-179	12.7	33
199	Personalisierte Medizin in der H�matoonkologie. <i>Info Onkologie</i> , 2018 , 21, 49-55		
198	Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1007-1016	2.2	43
197	Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	3
196	Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial). <i>British Journal of Haematology</i> , 2018 , 183, 235-241	4.5	2
195	Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. <i>Blood</i> , 2018 , 132, 1703-1713	2.2	142
194	Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. <i>Oncogene</i> , 2018 , 37, 5269-5280	9.2	42
193	Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. <i>Leukemia</i> , 2017 , 31, 1217-1220	10.7	37
192	Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. <i>Leukemia</i> , 2017 , 31, 2020-2028	10.7	80
191	Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. <i>Leukemia</i> , 2017 , 31, 1306-1313	10.7	56
190	Precision oncology for acute myeloid leukemia using a knowledge bank approach. <i>Nature Genetics</i> , 2017 , 49, 332-340	36.3	155

189	Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group. <i>Leukemia</i> , 2017 , 31, 1012-1015	10.7	13
188	Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. <i>Molecular Therapy</i> , 2017 , 25, 165-180	11.7	114
187	Human T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. <i>Nature Immunology</i> , 2017 , 18, 393-401	19.1	146
186	Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization. <i>Haematologica</i> , 2017 , 102, e170-e174	6.6	8
185	Therapy-related myeloid neoplasms. <i>Current Opinion in Hematology</i> , 2017 , 24, 152-158	3.3	22
184	Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2017 , 96, 1361-1372	3	38
183	IDH-Inhibitoren. <i>Onkologe</i> , 2017 , 23, 632-638	0.1	1
182	An optimized lentiviral vector system for conditional RNAi and efficient cloning of microRNA embedded short hairpin RNA libraries. <i>Biomaterials</i> , 2017 , 139, 102-115	15.6	12
181	Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1095-1101	4.7	65
180	The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. <i>Annals of Hematology</i> , 2017 , 96, 895-904	3	4
179	Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSSG BiO). <i>Annals of Hematology</i> , 2017 , 96, 1993-2003	3	79
178	Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients. <i>European Journal of Haematology</i> , 2017 , 99, 544-552	3.8	4
177	Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. <i>Leukemia</i> , 2017 , 31, 1286-1295	10.7	39
176	Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset. <i>Frontiers in Immunology</i> , 2017 , 8, 1100	8.4	7
175	Axl blockade in vitro and in patients with high-risk MDS by the small molecule inhibitor BGB324. <i>Journal of Clinical Oncology</i> , 2017 , 35, 7059-7059	2.2	2
174	VH1 Family Immunoglobulin Repertoire Sequencing after Allogeneic Hematopoietic Stem Cell Transplantation. <i>PLoS ONE</i> , 2017 , 12, e0168096	3.7	5
173	miR-625-3p is upregulated in CD8+ T cells during early immune reconstitution after allogeneic stem cell transplantation. <i>PLoS ONE</i> , 2017 , 12, e0183828	3.7	7
172	Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy. <i>Oncotarget</i> , 2017 , 8, 73871-73883	3.3	8

171	MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development. <i>Experimental Hematology</i> , 2016 , 44, 1166-1171	3.1	13
170	Genomic Classification and Prognosis in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2016 , 374, 2209-2221	59.2	1999
169	Oxaliplatin pharmacokinetics on hemodialysis in a patient with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2016 , 95, 649-50	3	2
168	miR-21 promotes fibrosis in an acute cardiac allograft transplantation model. <i>Cardiovascular Research</i> , 2016 , 110, 215-26	9.9	49
167	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. <i>Hematology American Society of Hematology Education Program</i> , 2016 , 2016, 24-32	3.1	16
166	Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG). <i>Blood</i> , 2016 , 128, 1207-1207	2.2	9
165	Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial. <i>Blood</i> , 2016 , 128, 449-449	2.2	15
164	TCR Diversity Is a Predictive Marker for Donor Lymphocyte Infusion Response. <i>Blood</i> , 2016 , 128, 4605-4605		2
163	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. <i>Blood</i> , 2016 , 128, 589-589	2.2	11
162	Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo. <i>Blood</i> , 2016 , 128, 745-745	2.2	7
161	A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2016 , 128, 99-99	2.2	33
160	A first-in-patient phase I study of BGB324, a selective Axl kinase inhibitor in patients with refractory/relapsed AML and high-risk MDS.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2561-2561	2.2	12
159	A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7060-7060	2.2	5
158	Clinical Impact of KMT2C and SPRY4 Expression Levels in Intensively Treated Younger Adult Acute Myeloid Leukemia Patients. <i>Blood</i> , 2016 , 128, 1663-1663	2.2	
157	Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA). <i>Blood</i> , 2016 , 128, 4038-4038	2.2	
156	Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 3995-3995	2.2	1
155	The miRNA-193 Family Is a Potent Tumor-Suppressor and a Biomarker for Poor Prognosis in Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 1534-1534	2.2	0
154	Genetic Profile of Acute Erythroid Leukemia. <i>Blood</i> , 2016 , 128, 40-40	2.2	

153	HSC Hierarchy in Primary Myelofibrosis. <i>Blood</i> , 2016 , 128, 4285-4285	2.2	
152	Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening. <i>Current Cancer Drug Targets</i> , 2016 , 16, 818-828	2.8	15
151	Clonal Hematopoiesis of Indeterminate Potential. <i>Deutsches A&#x0308;rzteblatt International</i> , 2016 , 113, 317-22	2.5	46
150	MP475OXALIPLATIN PHARMACOKINETICS ON HEMODIALYSIS IN A PATIENT WITH DIFFUSE LARGE B-CELL LYMPHOMA. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, i499-i499	4.3	
149	RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. <i>Cancer Cell</i> , 2016 , 30, 75-91	24.3	89
148	Letter to the Editor: Production of Mature Healthy Hematopoietic Cells from Induced Pluripotent Stem Cells Derived from an AML Diagnostic Sample Containing the t(8;21) Translocation. <i>Stem Cells</i> , 2016 , 34, 797-9	5.8	5
147	Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group. <i>Leukemia</i> , 2016 , 30, 2248-2250	10.7	28
146	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. <i>Hematology American Society of Hematology Education Program</i> , 2016 , 2016, 24-32	3.1	18
145	Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. <i>Leukemia</i> , 2016 , 30, 1672-81	10.7	65
144	Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. <i>Leukemia</i> , 2016 , 30, 1708-15	10.7	31
143	RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. <i>Leukemia</i> , 2016 , 30, 2160-2168	10.7	121
142	Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform. <i>Molecular Therapy</i> , 2016 , 24, 1216-26	11.7	17
141	Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML. <i>Experimental Hematology</i> , 2016 , 44, 713-726.e14	3.1	8
140	Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators. <i>Rna</i> , 2016 , 22, 1535-49	5.8	28
139	Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects. <i>Clinical Cancer Research</i> , 2015 , 21, 2388-98	12.9	66
138	Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective analysis of the European Society of Blood and Marrow Transplantation. <i>Hematologica</i> , 2015 , 100, 122-31	6.6	41
137	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , 2015 , 16, 1025-1036	21.7	113
136	MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. <i>Experimental Hematology</i> , 2015 , 43, 858-868.e7	3.1	26

135	Enigmas of IDH mutations in hematology/oncology. <i>Experimental Hematology</i> , 2015 , 43, 685-97	3.1	21
134	How I treat refractory and early relapsed acute myeloid leukemia. <i>Blood</i> , 2015 , 126, 319-27	2.2	185
133	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. <i>British Journal of Haematology</i> , 2015 , 169, 694-700	4.5	71
132	Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. <i>Leukemia</i> , 2015 , 29, 1942-5	10.7	13
131	Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling. <i>Leukemia</i> , 2015 , 29, 157-68	10.7	18
130	Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, e122-4	6.6	12
129	ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. <i>Haematologica</i> , 2015 , 100, 324-30	6.6	67
128	Effective Treatment of Human CML By RNAi In Vivo in a Xenotransplantation Mouse Model. <i>Blood</i> , 2015 , 126, 1261-1261	2.2	2
127	Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG). <i>Blood</i> , 2015 , 126, 226-226	2.2	3
126	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015 , 126, 2586-2586	2.2	1
125	Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606). <i>Blood</i> , 2015 , 126, 322-322	2.2	30
124	Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 352-352	2.2	2
123	Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 3744-3744	2.2	7
122	Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study. <i>Blood</i> , 2015 , 126, 3789-3789	2.2	3
121	Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG). <i>Blood</i> , 2015 , 126, 3818-3818	2.2	0
120	Dissecting Genetic and Phenotypic Heterogeneity to Map Molecular Phylogenies and Deliver Personalized Outcome and Treatment Predictions in AML. <i>Blood</i> , 2015 , 126, 803-803	2.2	2
119	Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data. <i>Blood</i> , 2015 , 126, 85-85	2.2	1
118	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. <i>Blood</i> , 2015 , 126, 907-907	2.2	73

117	Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 912-912	2.2	5
116	Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis. <i>Blood</i> , 2015 , 126, 224-224	2.2	
115	The Role of microRNA-155 in Mouse Models of MLL -AML. <i>Blood</i> , 2015 , 126, 2446-2446	2.2	
114	The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 1244-1244	2.2	
113	A Tumor Suppressor microRNA Defines the Leukemic Hierarchy in Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 3653-3653	2.2	
112	Patient Derived Xenotransplantation Model of Atypical Chronic Myeloid Leukemia (aCML). <i>Blood</i> , 2015 , 126, 2836-2836	2.2	
111	Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. <i>Leukemia</i> , 2014 , 28, 1552-5	10.7	47
110	Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. <i>Blood</i> , 2014 , 123, 914-20	2.2	129
109	Low frequency of calreticulin mutations in MDS patients. <i>Leukemia</i> , 2014 , 28, 1933-4	10.7	4
108	Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia. <i>Annals of Hematology</i> , 2014 , 93, 977-82	3	5
107	Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. <i>Haematologica</i> , 2014 , 99, 1456-64	6.6	22
106	Genetic characterization of acquired aplastic anemia by targeted sequencing. <i>Haematologica</i> , 2014 , 99, e165-7	6.6	36
105	Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13. <i>Blood</i> , 2014 , 124, 3608-12	2.2	21
104	Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype. <i>BMC Genomics</i> , 2014 , 15, 784	4.5	17
103	Genetic deletion of SEPT7 reveals a cell type-specific role of septins in microtubule destabilization for the completion of cytokinesis. <i>PLoS Genetics</i> , 2014 , 10, e1004558	6	65
102	TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 824-32	5	18
101	All-in-One inducible lentiviral vector systems based on drug controlled FLP recombinase. <i>Biomaterials</i> , 2014 , 35, 4345-56	15.6	18
100	Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2014 , 93, 193-202	3	7

99	Results of the Evaluation of NGS in AML-Diagnostics (ELAN) Study: An Inter-Laboratory Comparison Performed in 10 European Laboratories. <i>Blood</i> , 2014 , 124, 2374-2374	2.2	1
98	Prognostic Impact of Splicing Factor Mutations in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014 , 124, 3171-3171	2.2	1
97	A Novel Inhibitor of Mutant IDH1 Induces Differentiation in Vivo and Prolongs Survival in a Mouse Model of Leukemia. <i>Blood</i> , 2014 , 124, 3598-3598	2.2	7
96	The Metabolite R-2-Hydroxyglutarate (R2HG) Collaborates with HoxA9 to Induce Monocytic Leukemia. <i>Blood</i> , 2014 , 124, 366-366	2.2	1
95	Casein Kinase 1A1 (CSNK1A1) Is Recurrently Mutated in MDS Patients with Deletion of Chromosome 5q. <i>Blood</i> , 2014 , 124, 4643-4643	2.2	1
94	Cell fate decisions in malignant hematopoiesis: leukemia phenotype is determined by distinct functional domains of the MN1 oncogene. <i>PLoS ONE</i> , 2014 , 9, e112671	3.7	14
93	Dose Dependent Role of Gfi1 in Human MDS and AML and Its Suitability As a Novel Target. <i>Blood</i> , 2014 , 124, 777-777	2.2	
92	EZH2 Mutations Are Drivers of Clonal Hematopoiesis and Leukemic Transformation in a Mouse Model of Primary Myelofibrosis. <i>Blood</i> , 2014 , 124, 3211-3211	2.2	
91	Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). <i>Blood</i> , 2014 , 124, 1254-1254	2.2	
90	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Celtram and Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014 , 124, 324-324	2.2	
89	Hoxa9/Meis1 Mediate Leukemic Programming through MicroRNA-155. <i>Blood</i> , 2014 , 124, 884-884	2.2	
88	In Vivo Methylome Changes in Purified Peripheral Blood Blasts and T Cells of AML Patients Treated with Decitabine: Statistical Modelling of a Hypomethylation Response. <i>Blood</i> , 2014 , 124, 870-870	2.2	
87	High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 2304-2304	2.2	
86	Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia. <i>Annals of Hematology</i> , 2013 , 92, 1079-90	3	23
85	Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. <i>Annals of Hematology</i> , 2013 , 92, 315-23	3	40
84	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). <i>Blood</i> , 2013 , 121, 4769-77	2.2	129
83	Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. <i>Blood</i> , 2013 , 122, 2443-52	2.2	149
82	Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. <i>Annals of Hematology</i> , 2013 , 92, 747-58	3	44

81	SETBP1 mutation analysis in 944 patients with MDS and AML. <i>Leukemia</i> , 2013 , 27, 2072-5	10.7	55
80	Analysis of NUP98/NSD1 translocations in adult AML and MDS patients. <i>Leukemia</i> , 2013 , 27, 750-4	10.7	34
79	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. <i>Blood</i> , 2013 , 122, 2877-87	2.2	165
78	Myelodysplastic syndromes are induced by histone methylation-filtering ASXL1 mutations. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4627-40	15.9	111
77	Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial. <i>Blood</i> , 2013 , 122, 1288-1288	2.2	3
76	Expression Of Hedgehog Pathway Mediator Gli2 Represents a Clinically Negative Prognostic Marker In Acute Myeloid Leukemia and Its Inhibitor GANT61 Exerts Anti-Leukemic Effects In Vitro. <i>Blood</i> , 2013 , 122, 53-53	2.2	3
75	Gfi1 As a Novel Prognostic Marker and Tumor Suppressor In Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 2516-2516	2.2	
74	Analysis Of Micro-RNA-142 Mutations In a Cohort Of 944 Patients With MDS and AML. <i>Blood</i> , 2013 , 122, 2804-2804	2.2	
73	Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome. <i>Blood</i> , 2013 , 122, 2555-2555	2.2	
72	Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG). <i>Blood</i> , 2013 , 122, 1332-1332	2.2	
71	The Clinical and Prognostic Influence Of Mutations In The Cohesin Complex In Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 1314-1314	2.2	
70	Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT. <i>Blood</i> , 2013 , 122, 2092-2092	2.2	
69	C-Terminal-Truncating ASXL1 Mutations Induce MDS Via Inhibition Of PRC2. <i>Blood</i> , 2013 , 122, 471-471	2.2	
68	ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2012 , 158, 208-215	4.5	7
67	Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. <i>Blood</i> , 2012 , 119, e96-9	2.2	60
66	Update on cytogenetic and molecular changes in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2012 , 53, 525-36	1.9	19
65	Functional role of BAALC in leukemogenesis. <i>Leukemia</i> , 2012 , 26, 532-6	10.7	31
64	Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. <i>Blood</i> , 2012 , 119, 3578-84	2.2	313

63	Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. <i>Annals of Hematology</i> , 2012 , 91, 1221-33	3	32
62	Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 689-95	5	88
61	SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. <i>Leukemia</i> , 2012 , 26, 1137-40	10.7	72
60	Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia. <i>Leukemia</i> , 2012 , 26, 289-95	10.7	28
59	Clinical Impact of TERT A1062T Mutations in Younger Patients with Acute Myeloblastic Leukemia. <i>Blood</i> , 2012 , 120, 1381-1381	2.2	1
58	Prognostic Effect of Mutations in the Splicing Gene Machinery in 339 Patients with MDS or Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012 , 120, 357-357	2.2	2
57	Impact of ASXL1 Mutations On Outcome After Reduced Intensity Allograft in Patients with Myelofibrosis. <i>Blood</i> , 2012 , 120, 1740-1740	2.2	
56	Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis. <i>Blood</i> , 2012 , 120, 770-770	2.2	
55	Frequency and Prognostic Impact of NUP98/NSD1 Translocations in Adult AML and MDS Patients. <i>Blood</i> , 2012 , 120, 1402-1402	2.2	0
54	Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. <i>Blood</i> , 2011 , 118, 3350-8	2.2	81
53	Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2889-96	2.2	306
52	Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. <i>Haematologica</i> , 2011 , 96, 1870-3	6.6	57
51	Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. <i>Blood</i> , 2011 , 117, 4561-8	2.2	81
50	DNMT3A mutations are rare in childhood acute myeloid leukemia. <i>Haematologica</i> , 2011 , 96, 1238-40	6.6	30
49	FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. <i>Haematologica</i> , 2011 , 96, 681-6	6.6	35
48	Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. <i>Cancer Cell</i> , 2011 , 20, 39-52	24.3	68
47	Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. <i>Annals of Hematology</i> , 2011 , 90, 273-81	3	12
46	Genetic changes of miR-182 G106A: rather a polymorphism than a somatic mutation. <i>Annals of Hematology</i> , 2011 , 90, 1107-9	3	1

45	Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. <i>Annals of Hematology</i> , 2011 , 90, 1047-58	3	24
44	Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. <i>Leukemia</i> , 2011 , 25, 1704-10	10.7	57
43	Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 682-9	2.2	47
42	Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2499-506	2.2	220
41	Reply to S. Masuda. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4593-4594	2.2	1
40	All-Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia [Results of the AMLSG 07-04 Randomized Treatment Trial. <i>Blood</i> , 2011 , 118, 80-80	2.2	12
39	ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML. <i>Blood</i> , 2011 , 118, 3554-3554	2.2	
38	Mutations of the Spliceosome Complex Genes Occur In Adult Patients but Are Very Rare In Children with Myeloid Neoplasia. <i>Blood</i> , 2011 , 118, 2797-2797	2.2	
37	Next Generation Sequencing for Minimal Residual Disease Monitoring in AML Patients with FLT3-ITD. <i>Blood</i> , 2011 , 118, 3548-3548	2.2	
36	The hematopoietic growth factors in acute leukemia: a European perspective. <i>Cancer Treatment and Research</i> , 2011 , 157, 339-62	3.5	3
35	Reply to I.H.I.M. Hollink et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e527-e528	2.2	4
34	Phosphoinositide phospholipase Cbeta1 (PI-PLCbeta1) gene in myelodysplastic syndromes and cytogenetically normal acute myeloid leukemia: not a deletion, but increased PI-PLCbeta1 expression is an independent prognostic factor. <i>Journal of Clinical Oncology</i> , 2010 , 28, e384-7;	2.2	3
33	Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 578-85	2.2	109
32	Biologic and experimental variation of measured cancer stem cells. <i>Cell Cycle</i> , 2010 , 9, 909-12	4.7	5
31	Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2356-64	2.2	193
30	IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. <i>Haematologica</i> , 2010 , 95, 1668-74	6.6	155
29	Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2010 , 116, 614-6	2.2	146
28	Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3. <i>Blood</i> , 2010 , 115, 4071-82	2.2	26

27	Extrinsic signals determine myeloid-erythroid lineage switch in MN1 leukemia. <i>Experimental Hematology</i> , 2010 , 38, 174-9	3.1	4
26	An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2010 , 34, 196-202	2.7	38
25	MN1 Inhibits Myeloid Differentiation by Transcriptional Repression of EGR2. <i>Blood</i> , 2010 , 116, 229-229	2.2	1
24	Mir-223 Is Dispensable for the Onset of Acute Myeloid Leukemia. <i>Blood</i> , 2010 , 116, 501-501	2.2	1
23	Functional Role of BAALC In Leukemogenesis. <i>Blood</i> , 2010 , 116, 4194-4194	2.2	
22	FLT3-ITD and Age Are the Major Prognostic Factors In Relapsed AML with Normal Karyotype. <i>Blood</i> , 2010 , 116, 1719-1719	2.2	1
21	Competition In Engraftment of Normal Hematopoietic Stem Cells and Leukemic Stem Cells. <i>Blood</i> , 2010 , 116, 4836-4836	2.2	
20	High-affinity neurotrophin receptors and ligands promote leukemogenesis. <i>Blood</i> , 2009 , 113, 2028-37	2.2	40
19	Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. <i>Blood</i> , 2009 , 113, 1432-43	2.2	87
18	Priming reloaded?. <i>Blood</i> , 2009 , 114, 925-6; author reply 926-7	2.2	3
17	Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. <i>Blood</i> , 2009 , 114, 3983-93	2.2	63
16	A Potent Stimulator of Self-Renewal in Combination with MEIS1 Overexpression Allows the Transformation of Late Committed Myeloid Progenitors.. <i>Blood</i> , 2009 , 114, 1434-1434	2.2	
15	Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3. <i>Experimental Hematology</i> , 2008 , 36, 845-59	3.1	52
14	In-depth characterization of the microRNA transcriptome in a leukemia progression model. <i>Genome Research</i> , 2008 , 18, 1787-97	9.7	148
13	Comprehensive Profiling of Micrnas in Murine Hematopoietic Stem Cells and Lineages Using a Microfluidics Approach. <i>Blood</i> , 2008 , 112, 2468-2468	2.2	1
12	Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines. <i>Seminars in Hematology</i> , 2007 , 44, 148-56	4	27
11	MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. <i>Blood</i> , 2007 , 110, 1639-47	2.2	117
10	An Open, Phase I Study of Cediranib in Patients with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007 , 110, 895-895	2.2	

9	Neurotrophin Receptors and Ligands Are Highly Expressed in Acute Leukemia and Promote Leukemogenesis.. <i>Blood</i> , 2007 , 110, 696-696	2.2	
8	Recombinant human erythropoietin in the treatment of nonrenal anemia. <i>Annals of Hematology</i> , 2006 , 85, 69-78	3	8
7	High meninoma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. <i>Blood</i> , 2006 , 108, 3898-905	2.2	194
6	Cytotoxicity determination without photochemical artifacts. <i>Cancer Letters</i> , 2005 , 223, 57-66	9.9	10
5	Colony-stimulating factors in the management of neutropenia and its complications. <i>Annals of Hematology</i> , 2005 , 84, 697-708	3	21
4	MN1 Expression Predicts Prognosis of Acute Myeloid Leukemia with Normal Cytogenetics.. <i>Blood</i> , 2005 , 106, 2351-2351	2.2	
3	Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. <i>Haematologica</i> , 2005 , 90, 1484-92	6.6	59
2	Drug-Response Signature Predicts Outcome in Adult Acute Myeloid Leukemia and Associates Poor Response with Molecular Characteristics of Hematopoietic Stem Cells.. <i>Blood</i> , 2004 , 104, 2024-2024	2.2	
1	Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes		2